The Catalyst - Newsletter December 2025 Jan 8 Written by Cameron Smith Cameron Smith Previous Previous Collaborations Pharmaceuticals, Inc. demonstrates a treatment for CLN1 Batten disease crosses the blood-brain-barrier Next Next Collaborations Pharmaceuticals and UTMB awarded a $1,999,195 contract for Pyronaridine as an oral Treatment for Ebola
